We are 2-chloro-3-[4-(4-chlorophenyl)cyclohexyl]naphthalene-1,4-dione CAS:153977-22-1 manufacturer and supplier in China, Pls send inquiry of to firstname.lastname@example.org of visit www.nbinno.com our official website should you have any interests
Chemical Name: 2-chloro-3-[4-(4-chlorophenyl)cyclohexyl]naphthalene-1,4-dione
Molecular Formula: C22H18Cl2O2
Molecular Weight: 385.28300
Physical and Chemical Properties:
Density: 1.34g / cm3
Boiling point: 517.4ºC at 760 mmHg
Melting point: /
Flash point: 216.1ºC
Refractive index: 1.639
25kg cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Atovaquone CAS:95233-18-4
Related News: Genzyme Pharmaceuticals develops and manufactures chemically synthesized pharmaceutical materials and technologies for the global pharmaceutical industry and focuses on lipids, peptides, carbohydrates, oligonucleotides, and custom small molecules.4-Bromo-2,6-diphenylpyrimidine CAS:40734-24-5 FT819 is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line with complete elimination of T-cell receptor (TCR) expression and a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus.Diethyl ((2-(6-amino-9H-purin-9-yl)ethoxy)methyl)phosphonate CAS:116384-53-3 With the advancement of supply-side structural reforms, the production of bulk APIs in China will become more concentrated, and the technology will be further improved.1-Bromo-2-chloroethane Combining its core technological advantages such as ammonia oxidation, phosgenation, and fluorination, the company actively enters the field of fine and functional chemicals, and expands its focus to include polymer additives, replacement of phenolic polymer material monomers, and coating preservatives.China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.